Patent · US Active

Combination containing sGC activators and mineralocorticoid receptor antagonists

US11331308B2 · kind B2 · utility

0Cited by

7References

13Claims

0Family size

Assignee

Bayer Pharma Aktiengesellschaft · DE

Inventors

Peter Kolkhof · Wuppertal, DE
Peter Sandner · Wuppertal, DE

Key dates

Filing date	Oct 5, 2017
Grant date	May 17, 2022
Priority date	—
Expiry date	Oct 5, 2037

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P13/12
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to the combination of activators of soluble guanylate cyclase (sGC activators) with mineralocorticoid receptor antagonists (MR antagonists) and to the use of the combination for the treatment and/or prophylaxis of cardiac and cardiovascular disorders, of renal and cardiorenal disorders, of pulmonary and cardiopulmonary disorders and also for the treatment and/or prophylaxis of fibrotic disorders.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.